COTC is a bacterial metabolite that has anticancer activity and inhibits glyoxalase in the presence of glutathione (GSH) and the proliferation of HeLa cells, as well as reduces tumor growth and improves survival in an Ehrlich murine spontaneous adenocarcinoma model.
Glyoxalase I inhibitor 7 (Compound 6) is a potent inhibitor of glyoxalase I (Glo-I) with an IC50 of 3.65 μM. It exhibits potential as an anticancer agent [1].